511 results about "Animal disease" patented technology

Provided are immediate or prolonged administration of certain potassium ATP (K_ATP) channel openers to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving K_ATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of K_ATP channel openers that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are method of co-administering K_ATP channel openers with other drugs to treat diseases of humans and animals.

Disclosed are antisense oligonucleotide, polynucleotide, and peptide nucleic acid compounds that specifically bind to mammalian mRNA encoding a beta1-adrenoceptor polypeptide and that are useful in the control and/or treatment of cardiac dysfunction, hypertension, hypertrophy, myocardial ischemia, and other cardiovascular diseases in an affected mammal, and preferably, in a human subject. The antisense compounds disclosed herein, and pharmaceutical formulations thereof, provide sustained control of beta1-adrenoceptor expression over prolonged periods, and achieve therapeutic effects from as little as a single dose. Administration of these antisense compositions to approved animal models resulted in a decrease in blood pressure, but no significant change in heart rate. Use of such antisense compositions in the reduction of beta1-adrenoceptor polypeptides in a host cell expressing beta1-adrenoceptor-specific mRNA, and in the preparation of medicaments for treating human and animal diseases, and in particular, hypertension and other cardiac dysfunction is also disclosed.

The present invention relates to methods for treating or preventing a disease or disorder in an animal caused by infection by Mycoplasma hyopneumoniae (M. hyo) by administering to the animal at approximately three (3) to ten (10) days of age, a single dose of an effective amount of a M. hyo vaccine. The M. hyo vaccine can be a whole or partial cell inactivated or modified live preparation, a subunit vaccine, or a nucleic acid or DNA vaccine. The M. hyo vaccine administered in accordance with the present invention can be synthesized or recombinantly produced.

The present invention is a medical device for controlling the release of an active agent. The medical device has a supporting structure having a porous body disposed therein. At least one elution rate controlling matrix containing an effective amount of at least one active agent is disposed within the pores of the porous body in a manner that protects the matrix from mechanical damage. The medical device may therefore be used for controlled drug release applications. Additionally, the present invention discloses a method for using the medical device for the treatment and prevention of diseases in mammals. This invention further relates to a method for using the medical device for treating and preventing vascular diseases.

The present invention provides polypeptides that include an O-linked glycosylation site that is not present in the wild-type peptide. The polypeptides of the invention include glycoconjugates in which a species such as a water-soluble polymer, a therapeutic agent of a biomolecule is covalently linked through an intact O-linked glycosyl residue to the polypeptide. Also provided are methods of making the peptides of the invention and methods, pharmaceutical compositions containing the peptides and methods of treating, ameliorating or preventing diseased in mammals by administering an amount of a peptide of the invention sufficient to achieve the desired response.

Compositions and methods for treating mammalian disease characterized by undesirable angiogenesis by administering compounds of the general formula:

wherein the variables are defined in the specification.

The present invention relates to compositions and methods of treating a disease, such as diabetes, by implanting encapsulated biological material with a growth factor and conjugate into a patient in need of treatment. Several methods are presented to accomplish transplanting several different types of biological materials. This invention also provides methods of utilizing these encapsulated biological materials to treat different human and animal diseases or disorders by implanting them into several areas in the body including the subcutaneous site.

The invention relates to enterococcus faecium for feeding as well as a freeze-drying fungicide and applications thereof, and discloses enterococcus faecium LAB12 CGMCC (China General Microbiological Culture Collection Center) No.4847 which is grampositive cocci, has no spores, grows well on an MRS agar plate, forms a round bacterial colony with the diameter of 0.5-1mm within 48 hours and is used for feeding, and the bacterial colony is round, smooth and upheaved, and is a shape of grey white dewdrop; the enterococcus faecium grows in a facultative anaerobic condition; the growth temperature range is 10 DEG C-45 DEG C; the optimum growth temperature is 30 DEG C-40 DEG C; and the growth pH value is 4-10, and the optimum pH value is 6.0. The freeze-drying fungicide formed by the bacterial strain is nontoxic and harmless, is gastric juice resistant, is cholate resistant, has a high inhibitory effect for multiple harmful bacteria, has a long quality guarantee period, can be widely applied to birds and livestock breeding to strengthen the animal disease-resistant capability, and is expected to be the substitution of antibiotics for feeding.

The present invention discloses a composition and method of providing ionic forms or compounds of any combination of three metals to produce a product that can be used as a antimicrobial as defined by the U.S. Environmental Protection Agency (EPA) such as a hard surface disinfectant and as a foliar spray or water treatment for the control of various diseases in garden row, field and tree crops, on hard surface areas such as equipment from infected fields or in hospitals, homes, etc. as well as against a wide range of human, plant and animal diseases. Additionally, the composition of the present invention is able to be used to coat and otherwise treat and disinfect food products such as but not limited to fish and shellfish, meat, milk, poultry, eggs and irrigated crops (both food and nonfood crops) as well as non food products as defined in the EPA exemption from tolerance for copper and copper products. The composition may include inerts such as surfactants, detergents and buffers to adjust the pH. The composition remains soluble in water and is useful efficacious against the spread of bacteria, viruses and fungi and other pathogens within a source of water such as a reservoir or pool. Alternatively, the composition may be in aerosolized, misted, vaporized, fogged, humidified forms to produce micronized particles which are able to remain in suspension in the air for long periods of time in order to act on air-borne fungal spores and/or pathogens.

The present invention is directed to palatable ductile chewable veterinary composition for oral administration. The composition is capable of killing endo-parasites and ecto-parasites and/or can be used for treating prophylactic or curative animal diseases, and it is useful for the treatment of any warm-blooded non-human animal, including herd animals, like horses, cattle, sheep or poultry and preferably pets like dogs and cats. It consists basically of (A) an effective amount of one or more ingredients that are active against animal pests, pathogens or animal diseases; (B) meat flavoring; (C) partially gelatinized starch; (D) a softener; and (E) up to 9% water.

The invention encompasses compositions and methods for treating or preventing disorders in companion animals, wherein the compositions and methods include feeding the companion animal a composition including lipoic acid or a salt thereof.

The present invention relates to novel compounds selected from 2-(3-aminoaryl)amino-4-aryl-thiazoles that selectively modulate, regulate, and/or inhibit signal transduction mediated by certain native and/or mutant tyrosine kinases implicated in a variety of human and animal diseases such as cell proliferative, metabolic, allergic, and degenerative disorders. More particularly, these compounds are potent and selective c-kit inhibitors.

The invention discloses a technique for preparing antimicrobial peptide by using Bacillus subtilis, belonging to the technical field of bioengineering. By using Bacillus subtilis BRT39 capable of generating broad-spectrum high-efficiency antimicrobial peptide as a production strain, liquid seed preparation, fermentation liquid preparation, fermentation liquid pretreatment, antimicrobial peptide extraction and refinement, antimicrobial peptide dry powder preparation and other techniques are carried out to prepare the high-purity antimicrobial peptide finished product, wherein the activity recovery rate is up to higher than 43.5%. The invention has the advantages of simple technique, high yield of antimicrobial peptide, and high purity; the prepared antimicrobial peptide dry powder belongs to a natural antimicrobial agent and has no toxic or side effect, and thus, can be used as a food preservative, feed additive, agricultural biological control agent or animal disease preventing agent; and the antimicrobial peptide has the advantages of no toxicity, no residue, no drug resistance and high safety.

The present disclosure provides for a scientific formulation useful in the treatment and prevention of human and animal diseases. A biologically effective amount of each of the components of the formulation is administered to patients in pill (or capsule) form via multiple different and identifiable pills. The compounds of the formulation are segregated into different pill types, and contain various amounts of the compounds Curcumin, Genistein, Squalamine, Vitamin E, N-Acetyl-Cysteine, Methylselenocysteine, Zinc Gluconate, B Complex, Lentinen, Coenzyme Q10 Acetyl-L-Carnitine, Lipoic Acid, Resveratrol, and Vitamin C. Furthermore, Arabinoxylan and/or Peperine may be added to the various pill formulations.

The invention discloses a full-automatic animal carcass harmless treatment device. A power supply system, a closed container, a grinding system, a feeding system, a communication and electric control system, a temperature control heating system, a filtration system, a circulation system and a purification system are arranged on a trailer of a vehicle-mounted system of the device, wherein the grinding system is arranged in the closed container; the feeding system feeds materials into the closed container; the temperature control heating system heats the materials in the closed container; the filtration system disinfects steam which is generated in the closed container; the circulation system carries out filtration treatment and waste heat recovery on the materials; and the communication and electric control system is the system control device of the full-automatic animal carcass harmless treatment device. The animal carcass treatment device can completely inactivates common pathogenic microorganisms, and thoroughly realizes harmless treatment; and the device is an important technology and equipment for the emergency disposal of national and local serious animal diseases.

The present invention enables testing the effect of one or more test agent(s) on one or more animal(s) of a group of animals, preferably insects, to identify agents that affect behavioral properties of the animals. The invention is comprised of the steps of providing animals suitable for testing, bringing those animals into contact with the test agent(s), moving the animals from a growth container to isolate them, prepare and separate the animals for singulation, relocated the animals to a behavior arena, subject the animals to behavioral tracking to assess their behavioral state, and removing the animals from the behavioral tracking to facilitate iterative analysis of further groups. The invention enables a method for preparing a therapeutic compound for the treatment of an animal disease.

Provided are immediate or prolonged administration of certain salts of K_ATP channel openers such as diazoxide to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving K_ATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of the salts that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are method of co-administering the salts with other drugs to treat diseases of humans and animals.

A variety of human and animal diseases are associated with distortion of diversity of intestinal flora caused by such factors as unnatural diet and exposure to antibiotics. Probiotic compositions according to the present invention and methods for their generation are described which are designed to provide exposure to microorganisms in order to promote health of humans and other animals. Probiotic compositions are provided which include microorganisms isolated from the digestive system of an animal which is a traditional food source for a second type of animal. Such isolated microorganisms may be used directly in a probiotic composition and/or related method, and may also be cultured and/or amplified for such use.

The invention relates to a bursin extracting method and its application to curing disease and immunity, having important value in application in the aspects of heightening organismal immunity and acting as immunoenhancer, heightening effect of vaccine, etc., and able to heighten body fluid and cell immune functions of mammal at the same time. It can be used to prevent and cure infectious diseases and young animal diseases singly or together with other drugs such as antivirus and antibacterial drugs or immunomodulators, also be applied to animal vaccine as adjuvant or immunoenhancer to strengthen the disease-resistant ability and immunoresponse ability to peculiar antigens, thus heightening the immune effect.

A formulation of supplement is able to boost the natural cells, both increasing the population of the natural cells and enhancing the natural cell's activity. The formulation can be administered via different forms, such as tablet, injection, skin absorption and etc. This formulation comprises 16 different components, including Alpha Lipoic Acid, Arabinoxylin, Curcumin, Garlic, Genistein, Ginseng, Lentinan, Mistletoe, N-Acetylcysteine, Resveratrol, Selenium, Vitamin B Complex, Vitamin C, Vitamin D3, Vitamin E and Zinc. By virtue of enhancing the natural killer cells (NKC) in the body, the formation is helpful for the prevention and treatment of a number of different human or animal diseases, such as cancers and viral infections. In addition, certain synergistic effects have been observed between different components in the formulation, which further enhances the beneficial effect of the formulation.